BIG Breast International Group
We will find a cure for breast cancer through global research and collaboration.

BIG 1-97

BIG 1-97 is a phase III randomised double blind study of letrozole versus placebo in women with primary breast cancer completing five or more years of adjuvant tamoxifen.

This study found that in postmenopausal women, letrozole after completion of standard TAM Rx significantly improves disease-free survival (New England Journal of Medicine 2003).

Coordinating group: NCIC CTG

Patients accrual
Start date: August 1998
Closure date: September 2002
Target nr. of patients: 5184 (2380 in initial pilot phase)
Final accrual: 5187

Status: closed Identifier: NCT00003140

Scroll to top

Contact us

Breast International Group (BIG)-aisbl Blvd de Waterloo 121 B-1000 Brussels | Belgium VAT BE 0468 176 240